Evidence map›Paper›PMID 36242072›Full record

ArticleOrphanet journal of rare diseases2022

HINT1 neuropathy in Lithuania: clinical, genetic, and functional profiling.

Matilde Malcorps, Silvia Amor-Barris, Birute Burnyte, Ramune Vilimiene, Camila Armirola-Ricaurte, Kristina Grigalioniene, Alexandra Ekshteyn, Ausra Morkuniene, Arunas Vaitkevicius, Els De Vriendt and 6 more

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 4 countries.

Matilde Malcorps *Molecular Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
Silvia Amor-Barris *Molecular Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.ORCID 0000-0001-9379-0563
Birute Burnyte *Department of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Ramune VilimieneInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Camila Armirola-RicaurteMolecular Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
Kristina GrigalionieneDepartment of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Alexandra EkshteynMolecular Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
Ausra MorkunieneDepartment of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Arunas VaitkeviciusInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Els De VriendtMolecular Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
Jonathan BaetsTranslational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Steven S SchererDepartment of Neurology, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Laima AmbrozaityteDepartment of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Algirdas UtkusDepartment of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Albena Jordanova *Molecular Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium. Albena.jordanova@uantwerpen.vib.be.
Kristien Peeters *Molecular Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
University of Antwerp · BEVilnius University · LTUniversity of Pennsylvania · US

Funding

trainingU54NS065712 · NINDS · WAYNE STATE UNIVERSITY · PI SHY, MICHAEL E. · 2009 to 2023
$19.6M
NINDS NIH HHS U54 NS065712
6 · The paper itself

Abstract

backgroundRecessive loss-of-function variations in HINT1 cause a peculiar subtype of Charcot-Marie-Tooth disease: neuromyotonia and axonal neuropathy (NMAN; OMIM[#137200]). With 25 causal variants identified worldwide, HINT1 mutations are among the most common causes of recessive neuropathy. The majority of patients are compound heterozygous or homozygous for a Slavic founder variant (c.110G>C, p.Arg37Pro) that has spread throughout Eurasia and America.

resultsIn a cohort of 46 genetically unresolved Lithuanian patients with suspected inherited neuropathy, we identified eight families with HINT1 biallelic variations. Most patients displayed sensorimotor or motor-predominant axonal polyneuropathy and were homozygous for the p.Arg37Pro variant. However, in three families we identified a novel variant (c.299A>G, p.Glu100Gly). The same variant was also found in an American patient with distal hereditary motor neuropathy in compound heterozygous state (p.Arg37Pro/p.Glu100Gly). Haplotype analysis demonstrated a shared chromosomal region of 1.9 Mb between all p.Glu100Gly carriers, suggesting a founder effect. Functional characterization showed that the p.Glu100Gly variant renders a catalytically active enzyme, yet highly unstable in patient cells, thus supporting a loss-of-function mechanism.

conclusionOur findings broaden NMAN's genetic epidemiology and have implications for the molecular diagnostics of inherited neuropathies in the Baltic region and beyond. Moreover, we provide mechanistic insights allowing patient stratification for future treatment strategies.

Indexed as

Charcot-Marie-Tooth DiseaseIsaacs SyndromeHeterozygoteHumansLithuaniaMutationNerve Tissue ProteinsHINT1 protein, humanNerve Tissue ProteinsCharcot-Marie-Tooth diseaseHINT1LithuaniaNeuromyotoniaPeripheral neuropathy

Identifiers

PMID36242072
PMCPMC9569031
OpenAlexW4306249153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.